<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">  <head>    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>    <title>All Interactions with Zidovudine</title><link rel="stylesheet" href="css/insite.css" type="text/css"/><link rel="stylesheet" href="css/layout.css" type="text/css"/><link rel="stylesheet" href="css/topNav.css" type="text/css"/><!-- jquery javascript --><script type="text/javascript" src="script/jquery/load.js"><!--  --></script><script type="text/javascript" src="app-js/jquery.scrollTo.js"> </script><script type="text/javascript" src="app-js/jquery.cycle.js"> </script><script type="text/javascript" language="JavaScript">
        function openWindow(url,name){
            newWin = window.open(url,name,'status,toolbar,menubar,resizable,scrollbars,left=20,top=20,width=650,height=600')
            newWin.focus()
        }

        function openXWindow(url,name){
            newXWin = window.open(url,name)
            newXWin.focus()
        }

		/* BASED ON NEC DEMO.XML */
		   // REVEAL HIDDEN LOGIC QUESTION
				function branchNext (event) {
					$.log("BRANCHNEXT() :  enter");
					var n = $(this).children("input:checked").size();

					if (n)   {
						 var reveal = "." + $($(this).children("input:checked")).attr("name") + "-" + $($(this).children("input:checked")).val();

						 $(reveal).removeClass("hidden").addClass("question-revealed");
					}
			   }

		// HIDE TO-BE-REVEALED LOGIC QUESTIONS
			$(document).ready(function() { hideLogicQuestions($(document).children()[0]) });

			function hideLogicQuestions (element) {
				$.log("hideLogicQuestions() : enter");
				$(".hidden-question").each(function() {
					$(this).addClass("hidden").removeClass("question-revealed");
				});
		   }
		/* END FROM NEC DEMO.XML */


			function expand(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				/* CLOSE ALL SECTIONS AND RESET BUTTONS
				$(".expandable", section).addClass("hidden");
				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
				$(".expandAll", section).removeClass("hidden");
				$(".collapseAll", section).addClass("hidden");
				*/

				// OPEN SPECIFIED SECTION AND UPDATE ITS BUTTONS
				section.removeClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");

				// $(this).siblings(".expandAll").addClass("hidden");
				// $(this).siblings(".collapseAll").removeClass("hidden");
			}
			function collapse(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");

				$(this).siblings(".collapseAll").addClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");
			}

			function expandAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.removeClass("hidden");
				$(".expandable", section).removeClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".expand").addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");
				$(this).siblings(".collapseAll").removeClass("hidden");

				$(".expand", section).addClass("hidden");
				$(".collapse", section).removeClass("hidden");
			}
			function collapseAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(".expandable", section).addClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".collapse").addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");

				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
			}


			// connect the correct fuctions
			function sconnect(element) {
				$(".reveal-question", element).click(branchNext);

				$(".expand", element).click(expand);
				$(".expandAll", element).click(expandAll);
				$(".collapse", element).click(collapse);
				$(".collapseAll", element).click(collapseAll);
			}

			// load method for adding connections
			$(document).ready(function() {
				sconnect($(document).children()[0])
			 });

			 $(document).ready(function(){
			 $('.carousel ul').cycle({'prev':'.previous','next':'.next','play':'.play','pause':'.pause'});
			 $(".carousel-hidden").each(function () {
			 $(this).removeClass("carousel-hidden");
			 });
			 });


		</script><!--*********************************************************
    *************************************************************
    REPLACE GOOGLE ANALYTICS SCRIPT BEFORE PUBLISHING TO LIVESITE
    You can find the script in google-analytics.js **************
    *************************************************************
    **********************************************************--><script type="text/javascript">
   
     var _gaq = _gaq || [];
     _gaq.push(['_setAccount', 'UA-19627862-1']);
     _gaq.push(['_trackPageview']);
   
     (function() {
       var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
       ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
       var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
     })();
   
</script></head><body><div class="floatpage"><div id="ucsf"><a href="http://ucsf.edu/"><img src="images/masthead/ucsf.gif" alt="University of California, San Francisco Logo"/></a><p>University of California, San Francisco | <a href="http://www.ucsf.edu/about-ucsf/">About UCSF</a> | <a href="http://www.ucsf.edu/ucsf/search">Search UCSF</a> | <a href="http://www.ucsfhealth.org/">UCSF Medical Center</a></p></div><div id="header"><div style="float:left;"><a href="InSite" style="display:block;"><img src="images/masthead/splash-logo-top.gif" alt="HIV InSite"/></a><h1 class="site-description" style="clear:both; width: 475px;">Comprehensive, up-to-date information on HIV/AIDS treatment and prevention from the University of California San Francisco</h1></div><div class="site-sub-navigation"><a href="InSite">Home</a> | <a href="InSite?page=pb-00-00">Patient/Public</a> | <a href="InSite?page=Audio">Audio</a> | <a href="InSite?page=News">News</a> | <a href="InSite?page=Links">Links</a></div><div class="sitesearch"><form action="search" method="get" id="search"><input type="hidden" name="page" value="sr-00-00"/><input type="hidden" name="post" value="1"/><label for="SearchEntry">Search</label><input type="text" size="28" name="SearchEntry" id="SearchEntry" aria-label="Search"/><input type="submit" id="I1" value="Search" style="margin-left: 5px;"/></form></div><div id="site-navigation"><ul><li class="site-navigation"><a href="InSite?page=KB">Knowledge Base</a></li><li class="site-navigation"><a href="InSite?page=Treatment">Treatment</a></li><li class="site-navigation"><a href="InSite?page=Prevention">Prevention</a></li><li class="site-navigation"><a href="InSite?page=Policy">Policy Analysis</a></li><li class="site-navigation"><a href="InSite?page=cr-00-00">Global Response</a></li></ul></div></div><div id="content-target"><div><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="right"><font face="Arial, Helvetica" size="-2"><a href="http://hivinsite.ucsf.edu/InSite">Home</a> &gt; <a href="http://hivinsite.ucsf.edu/InSite?page=Treatment">Treatment</a> &gt; <a href="InSite?page=ar-00-02">Interactions</a></font></td></tr><tr><td><img alt="" src="images/transparent.gif" border="0" height="10" width="1"/></td></tr></tbody></table><div class="pgtitle">Database of Antiretroviral Drug Interactions</div><img alt="" src="images/greyline.gif"/><br/><p style="margin-top:0;padding-top:0;" class="kbrsec1">All Interactions with Zidovudine (Retrovir)</p><table class="datatable" width="100%"><thead><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Zidovudine</th><th>Effect on Drug Levels</th><th>Effect on Zidovudine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr></thead><tr><td valign="top" width="10%">Abacavir<sup><a href="#68">68</a></sup><div>(ABC)(Ziagen)</div></td><td valign="top">200 mg TID, 400 mg TID, 600 mg TID, 300 mg BID</td><td valign="top">200 mg TID, 300 mg BID</td><td valign="top">Inconsistent effect across all dosing regimens</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Abacavir<sup><a href="#66">66</a>, <a href="#67">67</a></sup><div>(ABC)(Ziagen)</div></td><td valign="top">600 mg x 1 dose</td><td valign="top">300 mg x 1 dose</td><td valign="top">No significant change</td><td valign="top">Zidovudine Cmax: decreased 20%; AUC: no significant change</td><td valign="top">-</td><td valign="top">Delayed zidovudine absorption</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Amprenavir<sup><a href="#60">60</a></sup><div>(APV)(Agenerase)</div></td><td valign="top">600 mg x 1 dose</td><td valign="top">300 mg x 1 dose</td><td valign="top">No significant change</td><td valign="top">Zidovudine AUC: increased 31%; Cmax: increased 40%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Atazanavir<sup><a href="#106">106</a>, </sup><div>(ATV)(Reyataz)</div></td><td valign="top">400 mg QD x 6 days</td><td valign="top">300 mg BID with lamivudine 150 mg BID x 6 days</td><td valign="top">Not studied</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Atovaquone<sup><a href="#81">81</a></sup><div>(Mepron)</div></td><td valign="top">750 mg Q12H</td><td valign="top">200 mg Q8H</td><td valign="top">No significant change</td><td valign="top">Zidovudine AUC: increased 31%; clearance: decreased 24%</td><td valign="top">Increased zidovudine effects</td><td valign="top">Inhibition of glucuronidation by atovaquone</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Zidovudine</th><th>Effect on Drug Levels</th><th>Effect on Zidovudine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Buprenorphine<sup><a href="#288">288</a></sup><div>(Suboxone)(Buprenex)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Clarithromycin<sup><a href="#358">358</a>, <a href="#81">81</a></sup><div>(Biaxin)</div></td><td valign="top">500 mg BID</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Zidovudine Cmax: increased 50%; AUC: no significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Delavirdine<sup><a href="#88">88</a></sup><div>(DLV)(Rescriptor)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Didanosine<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(ddI)(Videx)</div></td><td valign="top">200 mg (buffered formulation) Q12H x 3 days</td><td valign="top">200 mg Q8H x 3 days</td><td valign="top">No significant change</td><td valign="top">Zidovudine AUC: no significant change; Cmax: decreased 16.5%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Efavirenz<sup><a href="#90">90</a></sup><div>(EFV)(Sustiva)</div></td><td valign="top">600 mg QD x 14 days</td><td valign="top">300 mg Q12h x 14 days</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Emtricitabine<sup><a href="#132">132</a></sup><div>(FTC)(Emtriva)</div></td><td valign="top">200 mg QD x 7 days</td><td valign="top">300 mg BID x 7 days</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Zidovudine</th><th>Effect on Drug Levels</th><th>Effect on Zidovudine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Fluconazole<sup><a href="#81">81</a></sup><div>(Diflucan)(Diflucan)</div></td><td valign="top">400 mg QD</td><td valign="top">200 mg Q8H</td><td valign="top">-</td><td valign="top">Zidovudine AUC: increased 74%; Half-life: increased 128%</td><td valign="top">Increased zidovudine effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Fluconazole<sup><a href="#274">274</a></sup><div>(Diflucan)(Diflucan)</div></td><td valign="top">400 mg QD, 200 mg QD</td><td valign="top">500 mg QD, 250 mg QID</td><td valign="top">Fluconazole half-life: no significant change</td><td valign="top">Zidovudine half-life: increased</td><td valign="top">Increased zidovudine effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ganciclovir<sup><a href="#233">233</a>, <a href="#81">81</a></sup><div>(Cytovene)</div></td><td valign="top">1000 mg Q8H</td><td valign="top">-</td><td valign="top">No significant change</td><td valign="top">Zidovudine AUC: increased 19.5%; Cmax: increased 62%</td><td valign="top">Increased zidovudine effects</td><td valign="top">-</td><td valign="top"><p>Avoid combination if possible</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Indinavir<sup><a href="#16">16</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">1000 mg Q8H x 1 week</td><td valign="top">200 mg Q8H x 1 week</td><td valign="top">No significant change</td><td valign="top">Zidovudine AUC: increased 17-36%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">LAAM<sup><a href="#288">288</a></sup><div>(L-alpha-acetylmethadol)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Lamivudine<sup><a href="#81">81</a></sup><div>(3TC)(Epivir)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">No significant change</td><td valign="top">Zidovudine Cmax: increased 39%</td><td valign="top">Increased zidovudine effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Zidovudine</th><th>Effect on Drug Levels</th><th>Effect on Zidovudine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Lopinavir/ritonavir<sup><a href="#78">78</a></sup><div>(LPV/r)(Kaletra)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied</td><td valign="top">Not studied; may decrease zidovudine levels</td><td valign="top">Decreased zidovudine effects</td><td valign="top">Induction of glucuronidation by lopinavir/ritonavir</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Methadone<sup><a href="#191">191</a></sup><div>(Dolophine)(Dolophine)</div></td><td valign="top">-</td><td valign="top">oral and IV</td><td valign="top">No significant effect</td><td valign="top">Zidovudine AUC: increased 29% (oral zidovudine); AUC: increased 41% (IV zidovudine); clearance: decreased 26%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Methadone<sup><a href="#202">202</a></sup><div>(Dolophine)(Dolophine)</div></td><td valign="top">- </td><td valign="top">150 mg lamivudine/300 mg zidovudine (combination tablet)</td><td valign="top">No significant effect</td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Methadone<sup><a href="#81">81</a></sup><div>(Dolophine)(Dolophine)</div></td><td valign="top">30 to 90 mg QD</td><td valign="top">200 mg Q4H</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Naltrexone<sup><a href="#288">288</a></sup><div>(ReVia)(ReVia)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Nelfinavir<sup><a href="#24">24</a></sup><div>(NFV)(Viracept)</div></td><td valign="top">750 mg Q8H x 7-10 days</td><td valign="top">200 mg x 1 dose</td><td valign="top">Not studied</td><td valign="top">Zidovudine AUC: decreased 35%; Cmax: decreased 31%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Zidovudine</th><th>Effect on Drug Levels</th><th>Effect on Zidovudine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Nevirapine<sup><a href="#95">95</a></sup><div>(NVP)(Viramune)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Phenytoin<sup><a href="#81">81</a></sup><div>(Dilantin)(Dilantin)</div></td><td valign="top">300 mg QD</td><td valign="top">200 mg Q4H</td><td valign="top">No significant change</td><td valign="top">Zidovudine clearance: decreased 30%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Probenecid<sup><a href="#81">81</a></sup><div>(Benemid)(Benemid)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">May increase zidovudine levels</td><td valign="top">Increased zidovudine effects</td><td valign="top">Inhibition of glucuronidation and/or renal zidovudine secretion</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Ribavirin<sup><a href="#81">81</a></sup><div>(Rebetol, Virazole)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">Possibly decreased zidovudine effects</td><td valign="top">In vitro antagonism</td><td valign="top"><p>Avoid combination if possible</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ribavirin<sup><a href="#236">236</a></sup><div>(Rebetol, Virazole)</div></td><td valign="top">800 mg QD</td><td valign="top">300 mg BID</td><td valign="top">-</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Rifabutin<sup><a href="#81">81</a></sup><div>(Mycobutin)(Mycobutin)</div></td><td valign="top">300 mg QD x 7 or 14 days</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Zidovudine half-life: decreased 28%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Zidovudine</th><th>Effect on Drug Levels</th><th>Effect on Zidovudine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rifampin<sup><a href="#81">81</a></sup><div>(Rifampicin)(Rifadin)</div></td><td valign="top">600 mg QD</td><td valign="top">200 mg QD</td><td valign="top">-</td><td valign="top">Zidovudine AUC: decreased 48%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ritonavir<sup><a href="#55">55</a>, <a href="#58">58</a></sup><div>(RTV)(Norvir)</div></td><td valign="top">300 mg Q6H</td><td valign="top">200 mg Q8H</td><td valign="top">No significant change</td><td valign="top">Zidovudine Cmax: decreased 27%; AUC: decreased 26%</td><td valign="top">Decreased zidovudine effects</td><td valign="top">Unknown</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Stavudine<sup><a href="#86">86</a></sup><div>(d4T)(Zerit)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">Decreased stavudine effects</td><td valign="top">Competitive inhibition of intracellular phosphorylation of stavudine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">1250 mg BID with 100 mg ritonavir BID x 42 doses</td><td valign="top">300 mg BID x 43 doses</td><td valign="top">-</td><td valign="top">Zidovudine AUC: decreased 31%; Cmax: decreased 51%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">250 mg BID with 200 mg ritonavir BID</td><td valign="top">300 mg BID</td><td valign="top">-</td><td valign="top">Zidovudine AUC: decreased 42%; Cmax: decreased 46%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">500 mg BID with 100 mg ritonavir BID</td><td valign="top">300 mg x 1 dose</td><td valign="top">Tipranavir Cmin: decreased 23%</td><td valign="top">Zidovudine AUC: 43%; Cmax: decreased 61%; Zidovudine glucuronide Cmin: increased 52%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Zidovudine</th><th>Effect on Drug Levels</th><th>Effect on Zidovudine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">750 mg BID with 100 mg ritonavir BID</td><td valign="top">300 mg BID</td><td valign="top">-</td><td valign="top">Zidovudine AUC: decreased 36%; Cmax: decreased 49%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">750 mg BID with 200 mg ritonavir BID x 23 doses</td><td valign="top">300 mg x 1 dose</td><td valign="top">No significant change</td><td valign="top">Zidovudine AUC: decreased 33%; Cmax: decreased 56%; Cmin: increased 25%; Zidovudine glucuronide Cmin: increased 94%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Valproic acid<sup><a href="#221">221</a></sup><div>(Depakote, Depakene, Depacon)(Depakene, Depakote)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Zidovudine AUC: increased 100%</td><td valign="top">Increased zidovudine effects</td><td valign="top">Inhibition of glucuronidation</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Valproic acid<sup><a href="#81">81</a></sup><div>(Depakote, Depakene, Depacon)(Depakene, Depakote)</div></td><td valign="top">250 mg Q8H, 500 mg Q8H</td><td valign="top">100 mg Q8H</td><td valign="top">-</td><td valign="top">Zidovudine AUC: increased 79%</td><td valign="top">Increased zidovudine effects</td><td valign="top">Inhibition of glucuronidation</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Zalcitabine<sup><a href="#85">85</a></sup><div>(ddC)(Hivid)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#bbbbbb"><td class="cellleft" colspan="8">"-" indicates that there are no data available
                
            </td></tr></table><table cellspacing="2" cellpadding="0" border="0"><tr><td valign="top" class="cellrightblue"><a name="16"> </a>16:</td><td class="cellleft">Crixivan [package insert]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="19"> </a>19:</td><td class="cellleft">Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2003.</td></tr><tr><td valign="top" class="cellrightblue"><a name="24"> </a>24:</td><td class="cellleft">Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept 2004.</td></tr><tr><td valign="top" class="cellrightblue"><a name="55"> </a>55:</td><td class="cellleft">Norvir [package insert]. North Chicago, IL: Abbott Laboratories, 2008.</td></tr><tr><td valign="top" class="cellrightblue"><a name="58"> </a>58:</td><td class="cellleft">Cato A, Qian J, Hsu A, et al. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998;42:1788-93.</td></tr><tr><td valign="top" class="cellrightblue"><a name="60"> </a>60:</td><td class="cellleft">Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004.</td></tr><tr><td valign="top" class="cellrightblue"><a name="66"> </a>66:</td><td class="cellleft">Ziagen [package insert].  Research Triangle Park, NC: GlaxoWellcome Inc.; Sept 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="67"> </a>67:</td><td class="cellleft">Wang LH, Chittick GE, McDowell JA.  Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.  Antimicrob Agents Chemother 1999;43:1708-15.</td></tr><tr><td valign="top" class="cellrightblue"><a name="68"> </a>68:</td><td class="cellleft">McDowell JA, Lou Y, Symonds WS, et al.  Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.  Antimicrob Agents Chemother 2000;44:2061-67.</td></tr><tr><td valign="top" class="cellrightblue"><a name="78"> </a>78:</td><td class="cellleft">Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="81"> </a>81:</td><td class="cellleft">Retrovir [package insert]. Research Triangle Park, NC: GlaxoWellcome; Sept 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="84"> </a>84:</td><td class="cellleft">Videx EC [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="85"> </a>85:</td><td class="cellleft">Hivid [package insert]. Nutley, NJ:Roche Laboratories Inc.;2001</td></tr><tr><td valign="top" class="cellrightblue"><a name="86"> </a>86:</td><td class="cellleft">Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb Immunology; Sept 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="88"> </a>88:</td><td class="cellleft">Rescriptor [package insert]. La Jolla, California: Agouron Pharmaceuticals, Inc; June 2001.</td></tr><tr><td valign="top" class="cellrightblue"><a name="90"> </a>90:</td><td class="cellleft">Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Dec 2011.</td></tr><tr><td valign="top" class="cellrightblue"><a name="95"> </a>95:</td><td class="cellleft">Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="106"> </a>106:</td><td class="cellleft">Mummaneni V, Randall D, Geraldes M, et al. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with lamivudine (3TC) and zidovudine (ZDV) in healthy subjects. [abstract #H-1713]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="132"> </a>132:</td><td class="cellleft">Zong J, Blum MR, Chittick G, et al. A steady-state evaluation of the potential pharmacokinetic interaction between emtricitabine and zidovudine in healthy volunteers [abstract #A-1620]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="154"> </a>154:</td><td class="cellleft">Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="191"> </a>191:</td><td class="cellleft">McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (ACTG 262). JAIDS 1998;18:435-43.</td></tr><tr><td valign="top" class="cellrightblue"><a name="202"> </a>202:</td><td class="cellleft">Rainey PM, Friedland GH, Snidow JW, et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am J Addictions 2002;11:66-74.</td></tr><tr><td valign="top" class="cellrightblue"><a name="221"> </a>221:</td><td class="cellleft">Lertora JJ, Rege AB, Greenspan DL, et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1994;56:272-8.</td></tr><tr><td valign="top" class="cellrightblue"><a name="233"> </a>233:</td><td class="cellleft">Cimoch PJ, Lavelle J, Pollard R, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:227-34.</td></tr><tr><td valign="top" class="cellrightblue"><a name="236"> </a>236:</td><td class="cellleft">Gries J-M, Torriani FJ, Rodriguez-Torres M, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV co-infection: final results of a randomized clinical study [abstract #136LB]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="274"> </a>274:</td><td class="cellleft">Brockmeyer NH, Tillmann I, Mertins L, et al. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur J Med Res 1997;2:377-83.</td></tr><tr><td valign="top" class="cellrightblue"><a name="288"> </a>288:</td><td class="cellleft">McCance-Katz EF, Rainey PM, Friedland G, et al. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 2001;10:296-307.</td></tr><tr><td valign="top" class="cellrightblue"><a name="358"> </a>358:</td><td class="cellleft">Biaxin [package insert]. North Chicago, IL: Abbott Laboratories; 2003.</td></tr></table></div></div><div class="footer"><p class="footerlinks"><a href="InSite?page=About">About</a> | <a href="InSite?page=SM">Site Map</a> | <a href="fb?page=Feedback">Feedback</a> | <a href="InSite?page=Subscribe">Subscribe</a> | <a href="InSite?page=Donate">Donate</a> | <a href="InSite?page=Disclaimer">Disclaimer</a></p><p class="copyright"><a href="http://chi.ucsf.edu/" target="OffSite"><img src="images/footer/chi.gif" alt="UCSF - Center for HIV Information"/></a> HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2017, Regents of the University of California.</p></div></div></body></html>